Overview

Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
0
Participant gender:
All
Summary
To compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride
Criteria
Inclusion Criteria:

- Men and women 18 to 75 years of age, inclusive.

- Sexually active individuals participating in the study must use a medically acceptable
form of contraception during the study and for at least 15 days after the last dose of
test article

- Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria:

- Treatment with DVS-233 SR at any time in the past

- Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90
days of study day 1

- Known hypersensitivity to venlafaxine (IR or ER)